The product sales volume rose up, and the profit of the first half of the year of Hejia Pharmaceutical exceeded 114.48%

On July 19, 2022, the New Third Board Company Hejia Pharmaceutical (838641.NQ) disclosed the announcement of the semi -annual performance preview of 2022.

The announcement shows that the company's performance rose from January 1, 2022 to June 30, 2022.Hejia Pharmaceutical is expected to achieve a net profit attributable to shareholders of the listed company in the first half of the year, a net profit of 3010 to 32 million yuan, an increase of 114.48%to 128.02%year -on -year.

According to Hejia Pharmaceutical, the main reason for the first half of the year in 2022 is compared with the same period of the previous year. During the reporting period, the company's operating conditions were good, and the sales price and sales of major products increased compared with the same period of the previous year, and the level of profit increased.

According to public information, Hejia Pharmaceutical is a pharmaceutical manufacturing industry. The main business of cephalosporin antibiotic pharmaceutical intermediates and raw medicines are core, supplemented by the development, production and sales of chemical products trade and fine chemical products.

- END -